
Ironwood Pharmaceuticals Investor Relations Material
Latest events

Q4 2024
Ironwood Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Ironwood Pharmaceuticals Inc
Access all reports
Ironwood Pharmaceuticals, Inc., is a healthcare company that focuses on the development and commercialization of gastrointestinal products. The company develops linaclotide, a guanylate cyclase type-C agonist for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation under the LINZESS name in the United States and under the CONSTELLA name in Europe; and lesinurad for gout.
Key slides for Ironwood Pharmaceuticals Inc


Q3 2024
Ironwood Pharmaceuticals Inc


Q1 2024
Ironwood Pharmaceuticals Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IRWD
Country
🇺🇸 United States